Sevoflurane in COVID-19 ARDS (SevCov)

PHASE3CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

April 23, 2020

Primary Completion Date

June 25, 2021

Study Completion Date

July 16, 2021

Conditions
ARDS, HumanCoronavirus
Interventions
DRUG

Sevoflurane

Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS

DRUG

Intravenous drug

Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine

Trial Locations (4)

8063

Stadtspital Triemli, Zurich

8091

University Hospital Zuirch, Zurich

8596

Kantonsspital Münsterlingen, Münsterlingen

9007

Cantonal Hospital of St. Gallen, Sankt Gallen

All Listed Sponsors
collaborator

Kantonsspital Münsterlingen

OTHER

collaborator

Triemli Hospital

OTHER

collaborator

Cantonal Hospital of St. Gallen

OTHER

lead

University of Zurich

OTHER

NCT04355962 - Sevoflurane in COVID-19 ARDS (SevCov) | Biotech Hunter | Biotech Hunter